A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.

NCT02936102 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

154

Enrollment

INDUSTRY

Sponsor class

Stopped The early termination was based on a business decision that FAZ053 would no longer be formulated and was not a consequence of any safety concern.

Conditions

Advanced Solid Tumors
Triple Negative Breast Cancer
Chordoma and Alveolar Soft Part Sarcoma

Interventions

DRUG: FAZ053
DRUG: PDR001

Sponsor

Novartis Pharmaceuticals